This protocol addresses a specific subset of patients: alcohol-induced cardiomyopathy in the context of dilated cardiomyopathy where a genotype linked to elevated sudden cardiac death risk is present, left ventricular ejection fraction exceeds 35%, and no additional high-risk features are identified.
The patient presents with dilated cardiomyopathy and a genotype associated with high sudden cardiac death risk, combined with:
In this selected patient population, evidence supports consideration of an implantable device-based intervention directed at sudden cardiac death risk reduction. The decision hinges on the specific genotype and the absence of additional risk markers.
The complete protocol — including full selection criteria, procedural pathway, and clinical decision algorithm — is available via the link below.
DOI: 10.1093/eurheartj/ehad194